Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

A regiszterben nem jelölt feltételek

• Main Inclusion Criteria:
• Age ≥ 18 years and ≤ 75 years at time of study entry.
• Has histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix.
• The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages III-IVA.
• Diagnosed with PD-L1-positive (combined positive score ≥1).
• Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer.
• WHO/ECOG performance status of 0 or 1.
• Patient must have at least one measurable disease as defined by RECIST 1.1.
  • Main Exclusion Criteria:
• Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent o..
• Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 28 days from the end of treatment in the previous clinical study.
• Known history of serious allergy to any active ingredie or any excipients list in monoclonal antibody.
• The patient has other factors that, in the judgment of the investigator, may lead to forced early termination of the study.